Merck’s PREVYMIS gets Health Canada’s approval for CMV disease prevention

The latest approval was based on the results of a Phase III, double-blind, multi-centre, randomised, active comparator-controlled non-inferiority trial. Credit: Robina Weermeijer/Unsplash.